Postoperative Hemostasis and Fibrinolysis in Patients Undergoing Cardiopulmonary Bypass with or without Aprotinin Therapy

Summary

Intra- and postoperative blood loss during open heart surgery is reduced by approximately 50% when aprotinin, a potent inhibitor for plasmin and kallikrein, is administered during surgery. But whether aprotinin increases the risk of thrombotic complications remains controversial. The aim of this study was to evaluate the effects of aprotinin administration on coagulation and fibrinolysis during and after cardiopulmonary bypass (CPB). Thirty patients undergoing CPB were randomly assigned to two comparable groups for a double-blind study (16 patients receiving high-dose aprotinin, 14 patients receiving placebo). Patients’ plasma levels of ATM (thrombin-induced modified antithrombin III), FbDP (fibrin degradation products, D-Dimers), t-PA (tissue-type plasminogen activator) and PAI-1 (plasminogen activator inhibitor type 1) were measured at regular intervals. In both groups, ATM level increased during surgery (from less than 30 to 90-110 ng/ml) and returned to normal 24 h after surgery and remained unchanged thereafter. Aprotinin reduced this increase in ATM levels (p = 0.02 at 30 min after the start of CPB). The FbDP generated during surgery was greatly reduced in the aprotinin group (945 ng/ml) in comparison with the placebo group (1889 ng/ml, p = 0.004). After surgery, FbDP levels decreased in both groups with nadirs at 2nd day (placebo group: 940 ng/ml and aprotinin group: 865 ng/ml) indicating a hypo-fibrinolytic period. Then, the FbDP level in both groups started to increase up to the 9th day, in an identical manner. This postoperative hypofibrinolysis is related to the changes of t-PA and PAI-1 levels: immediately after surgery there was a 2’fold increase in t-PA level and a 4-5 fold increase in PAI-1 level in the two groups. During the following 24 h, t-PA levels decreased in both groups. In contrast, PAI-1 levels in the placebo group during the same time increased sharply to a maximum level (175.7 ng/ml). This further increase did not occur in the aprotinin group although it remained at a high level (79.2 ng/ml). The difference in the increase of PAI-1 between the 2 groups (value at 24 h minus preoperative value: Dl-Tl) was significantly different (p = 0.04). Then t-PA continued to decrease and PAI-1 began to decrease steadily. Total blood loss was significantly reduced by aprotinin therapy (3.06 ml/kg versus 5.86 ml/kg). The present study confirms the inhibitory effects of aprotinin on both fibrinolytic activity and blood coagulation activation during CPB, and reveals an hypofibrinolytic period that lasts 48 h after surgery in both aprotinin and placebo groups. This inhibition of fibrinolysis is apparently associated with high PAI-1 level. The data of this study also show that 2 days after aprotinin therapy, there is no prolonged effect of aprotinin on fibrinolysis. In addition, the lower level of PAI-1 in the aprotinin group after surgery might result from a protection of endothelial cells by aprotinin, suggesting an unexpected benefit of aprotinin therapy.

• References

• 1 Bick RL. Hemostasis defects associated with cardiac surgery, prothetic devices, and other extracorporeal circuits. Semin Thromb Hemost 1982; 11: 3249-80
• 2 Hunt BJ. Modifying perioperative blood loss. Blood Rev 1991; 5: 168-76
• 3 Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-97
• 4 Tanaka K, Morimoto T, Yada I, Kusagawa M, Deguchi K. Physiologic role of enhanced fibrinolytic activity during cardiopulmonary bypass in open heart surgery. Trans Am Soc Artif Intern Organs 1987; 33: 505-9
• 5 Lu H, Soria C, Commin PL, Soria J, Piwnica A, Schumann F, Regnier O, Legrand Y, Caen JP. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-7
• 6 Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. Circulation 1992; 86 (II): 405-9
• 7 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-61
• 8 Royston D. High-dose aprotinin therapy: a review of the first five years’ experience. J Cardiothorac Vase Anesthesia 1992; 6: 76-100
• 9 Royston D. Clinical effectiveness of aprotinin in heart surgery. In: Blood use in cardiac surgery Freidel N, Hetzer R, Royston D. (eds) New York: NY: Springer-Verlag; 1991. pp 208-20
• 10 Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991; 51: 936-41
• 11 Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, Sebening F, Richter JA. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990; 73: 1119-26
• 12 Bidstrup BP, Roystrom D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1990; 97: 364-72
• 13 van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-97
• 14 de Smet AAEA, Joen MCN, van Oeveren W, Roozendaal KJ, Harder MP, Eijsman L, Wildevuur CRH. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990; 100: 520-7
• 15 Cosgrove IIIDM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-8
• 16 Fraedrich G, Neukamm K, Schneider T. Safety and risk/benefit assessment of aprotinin in primary CABG. In: Blood use in Cardiac surgery Freidel N, Hetzer R, Royston D. (eds) New York: NY: Springer-Verlag; 1991. pp 201-31
• 17 Bidstrup BP, Underwood SR, Sapsford RN. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993; 105: 147-53
• 18 Tran-Thang C, Kruithof EKO, Atkinson J, Bachmann F. High-affinity binding sites for human glu-plasminogen unveiled by limited plasmic degradation of fibrin. Eur J Biochem 1986; 160: 599-604
• 19 Sorensen JV, Lassen MR, Borris LC, Jorgensen PS, Schott P, Weber S, Murphy R, Walenga J. Postoperative deep vein thrombosis and plasma levels of tissue plasminogen activator inhibitor. Thromb Res 1990; 60: 247-51
• 20 Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151: 1721-9
• 21 Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor PAI-1 binds to fibrin and inhibits tissue type plasminogen activator-mediated fibrin dissolution. J Biol Chem 1992; 267: 17128-35
• 22 Kassis J, Hirsh J, Podor TJ. Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. Blood 1992; 80: 1758-64
• 23 Paramo JA, Rifon J, Llorens R, Casares J, Paloma MJ, Rocha E. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary surgery. Haemostasis 1991; 21: 58-64
• 24 Amiral J, Vissac AM, Mimilla F, Grosley B. Assay of blood activation by measurement of AT Ill-serine esterases complexes (ATM) using a specific monoclonal antibody 4C9. Thromb Haemost 1989; 62: 479 (Abstr)
• 25 Soriae J, Soria C, Mirshahi M, Bouchex C, Pujade E, Perrot JY, Samama M, Bernadou A, Caen JP. Le complexe DDE. CR Acad Sci Paris 1987; 304 III (11) 307-311
• 26 Declerck PJ, Moreau H, Jespersen J, Gram J, Kluft C. Multicenter evaluation of commercial available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 1993; 70: 858-63
• 27 Sue-Ling HM, Johnston D, Verheijen JH, Kluft C, Philips DR, Davies JA. Indicators of depressed fibrinolytic activity in pre-operative prediction of deep venous thrombosis. Br J Surg 1987; 74: 275-8
• 28 Seifried E, Tanswell P, Ellbruck D, Haerer W, Schmidt A. Pharmacokinetics and hemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with myocardial infarction. Thromb Haemost 1989; 61: 497-501